Regulatory conflicts occur when two signals that individually trigger opposite cellular responses are present simultaneously. Here, we investigate regulatory conflicts in the bacterial response to antibiotic combinations. We use an Escherichia coli promoter-GFP library to study the transcriptional response of many promoters to either additive or antagonistic drug pairs at fine two-dimensional (2D) resolution of drug concentration. Surprisingly, we find that this data set can be characterized as a linear sum of only two principal components. Component one, accounting for over 70% of the response, represents the response to growth inhibition by the drugs. Component two describes how regulatory conflicts are resolved. For the additive drug pair, conflicts are resolved by linearly interpolating the single drug responses, while for the antagonistic drug pair, the growth-limiting drug dominates the response. Importantly, for a given drug pair, the same conflict resolution strategy applies to almost all genes. These results provide a recipe for predicting gene expression responses to antibiotic combinations.
INTRODUCTION
Cells respond to signals present in their environment by altering the transcription levels of their genes (Alberts, 2008; Ló pezMaury et al., 2008) . Global gene regulatory responses to changes in the cellular environment have been studied for many different organisms and environments. In particular, transcriptional responses to a wide range of specific signaling molecules as well as more general signals such as nutrients, stress conditions, and drugs have been characterized in great detail (Camilli and Bassler, 2006; Davies et al., 2009; Dwyer et al., 2007; Hughes et al., 2000; Kohanski et al., 2007 Kohanski et al., , 2008 Kohanski et al., , 2010 Kolodkin-Gal et al., 2008; Lee et al., 2010; Mesak et al., 2010; Shaw et al., 2003) . In their natural environments, cells are usually exposed to multiple signals simultaneously. Though the responses of specific genes to combinations of signals have been studied (Geva-Zatorsky et al., 2010; Kaplan et al., 2008; Kuhlman et al., 2007; Setty et al., 2003) , there has not been a systematic genome-wide investigation into responses to combined signals.
The number of possible combinations of signals a cell can be exposed to is huge even if we consider only a relatively small set of signals: For a set of N different signals, the number of pairwise combinations scales as N 2 , while the number of possible combinations of m signals scales as N m . In contrast, the information processing capabilities of the cellular machinery that has to detect and respond to these signals are probably rather limited. Hence, it is implausible that cells have evolved specific responses for each possible combination and each regulated gene-it is more likely that their response to a combination of signals is based on their responses to the individual signals. It is therefore possible that relatively simple, general rules connecting the cellular response to individual signals with the response to a combination of signals may exist. This possibility is highlighted by a recent study that revealed that the temporal response of 15 different protein levels in a human lung cancer cell line to combinations of anticancer drugs is a linear superposition of the individual drug responses (Geva-Zatorsky et al., 2010) . However, to reveal general rules, these issues will need to be explored in a range of different model systems, including prokaryotes. Moreover, genome-wide studies of drug combination effects at fine 2D resolution of drug concentration will be needed to achieve this goal. If it is indeed possible to identify rules that describe how the response to a combination of signals or drugs is determined by the responses to each of the individual signals or drugs, this could be extremely helpful in understanding complex cellular responses in situations such as apoptosis, where many competing signals are often present Janes et al., 2005; Janes et al., 2006) , and for the rational design of combination therapy.
The general question we set out to address is how gene regulatory conflicts are resolved. We define a gene regulatory conflict as a situation in which a gene is regulated in opposite directions by two signals or drugs present in a combination. For example, drug A might lead to the downregulation of a gene while drug B leads to its upregulation ( Figure 1A ). The response to the drug combination will certainly depend on the ratio of the two drug concentrations, but there are many possibilities for how the two responses could be combined. For example, cells might linearly interpolate (''average'') the conflicting individual drug responses ( Figure 1B ). Alternatively, they might respond to only one of the drugs, e.g., the drug that is present at the higher effective dose (''prioritized response'' [ Figure 1B] ). The prioritized response may be biased, i.e., genes may respond exclusively to one of the drugs even when it is only present at relatively low dosage ( Figure 1B ) (Geva-Zatorsky et al., 2010) . Finally, it is not clear whether the entire population of cells will respond uniformly to the drug combination: For example, individual cells could decide stochastically to prioritize their response to either one of the drugs ( Figure 1C) .
In bacteria, different antibiotics are known to elicit specific gene regulation programs that often affect a considerable fraction of the genome (Brazas and Hancock, 2005; Davies et al., 2006; Fajardo and Martínez, 2008; Goh et al., 2002; Kohanski et al., 2007 Kohanski et al., , 2008 Linares et al., 2006; Shaw et al., 2003; Tsui et al., 2004; Yim et al., 2007) . We therefore expect that many genes will be subject to regulatory conflicts in the presence of multiple different antibiotics, making this a promising model system for the investigation of conflict resolution in gene regulation. We used fluorescent reporters in Escherichia coli to measure the transcription of about 100 genes in response to a complete 2D gradient of two different pairs of antibiotics, which, at the level of growth inhibition, show additive and antagonistic drug interactions, respectively (Bliss, 1939; Chait et al., 2007; Loewe, 1928 Loewe, , 1953 Yeh and Kishony, 2007) . By simultaneously measuring the effect of the drugs on growth rate, we separated drug-specific effects on gene expression from nonspecific contributions through growth rate changes. We then applied principal component analysis (PCA) to identify characteristic ways in which cells respond to drug combinations.
RESULTS

Antibiotic Combinations Lead to Gene Regulatory Conflicts
To identify conflicts in gene regulation, we first investigated the bacterial gene expression response to three different bacteriostatic antibiotics applied individually: trimethoprim (TMP), spiramycin (SPR), and tetracycline (TET) ( Table 1) . This selection allowed us to compare pairs of drugs with similar modes of action (TET and SPR) and unrelated modes of action (TMP and SPR). We used an automated robotic system and an E. coli library of fluorescent transcriptional reporter strains (Shachrai et al., 2010; Zaslaver et al., 2006 Zaslaver et al., , 2009 , focusing on a genome-wide sample of 103 promoters that represent key cellular functions including metabolism, stress response, DNA repair, and ribosome synthesis (Table S1 ). We simultaneously measured changes in gene expression and growth rate across a range of antibiotic concentrations. The robotic system measured optical density (OD) and GFP fluorescence at multiple time points during exponential phase. We used antibiotic concentrations that slow but do not completely stop growth, since our main interest here is the cellular response in conditions where key cell functions are not too severely impaired. The exponential growth rate was obtained from the increase in OD over time (Figure 2A) , and gene expression level changes (g) were obtained from the effect of the drug on the average GFP signal per OD during exponential phase (g = [GFP/OD] / [GFP/OD] no drug ) ( Figure 2A and Experimental Procedures). These simultaneous measurements enabled us to compare the expression level of each promoter in the presence of different drugs at the same level of growth inhibition ( Figure 2B ).
When the responses of a given gene to different antibiotics are compared, several qualitatively different cases appear: Some promoters show no response to either of the two drugs; e.g., minC, which plays a role in cell division (Keseler et al., 2009 ), responds to neither TMP nor SPR ( Figure 2B ). Other promoters respond to only one of the drugs, e.g., pheL, which plays a role in amino acid biosynthesis (response exclusively to TMP) (Figure 2B) . Promoters that respond to both drugs can show a consistent response in which the sign of the regulation (up or down) is the same for both drugs. For example, this is the case for sodA, which plays a role in the oxidative stress response (Figure 2B) . However, there are also promoters showing conflicting responses: upregulated by one drug and downregulated by the other (e.g., cspA, a major cold shock protein) ( Figure 2B ). We next asked how frequent conflicting responses to antibiotic pairs are. To this end, we compared the gene regulation responses to antibiotics at a fixed level of growth inhibition (normalized growth rate g = 0.5) ( Figures 2C and 2D and Table  S1 ). Looking globally at the gene expression response of all promoters in our genome-wide sample, we found that conflicting responses (in which the directions of gene regulation are opposite) occur almost as often as consistent responses (in which the direction of gene regulation is the same) for the TMP-SPR drug pair (compare density of promoters in gray and white quadrants, respectively, in Figure 2C ). In contrast, for the TET-SPR pair, the majority of promoters show consistent responses to both antibiotics, with a smaller number of promoters showing conflicts (e.g., slp, dnaX) ( Figure 2D ). TET and SPR are both ribosomal inhibitors, though they act at different locations (Table 1) , while TMP acts through inhibition of folic acid synthesis (folA, dihydrofolate reductase, DHFR). These observations are in agreement with the simple expectation that drugs with different modes of action might present more cases of conflicting responses. (A) Example data demonstrating measurement of drug effect on growth rate and transcription reporters. Optical density (OD) and GFP expression from various promoters (shown, as an example, is the cspA promoter) are measured as a function of time for various drug concentrations. Shown are no drug (black), 65 mg/ml SPR (blue), and 1.3 mg/ml TMP (red). Top: Growth rates are defined by linear regression (green lines) to the OD curves. Bottom: Expression level g (green lines) is defined as GFP fluorescence intensity per OD, averaged over an OD range of exponential growth (shaded region) and normalized to no drug control (thus g = 1 for the no drug control). (B) Normalized expression levels (E x ) of example promoters cspA, sodA, minC, and pheL as a function of growth inhibition in various concentrations of SPR (blue) and TMP (red). Growth inhibition is the fraction by which the growth rate in the absence of drug is reduced. For each promoter X, E x is defined as expression level g x , normalized to the median expression level hgi of all promoters in the same drug concentration (Experimental Procedures). The three larger filled points for cspA correspond to the drug concentrations shown in (A). The promoter cspA shows a clear regulatory conflict for these two drugs. In contrast, sodA is consistently upregulated in response to both drugs, while pheL is only regulated in response to TMP and minC shows no response to either drug. Error bars correspond to two standard deviations estimated from replicate measurements done on different days (Experimental Procedures).
Different Promoters
(changes in expression at inhibition level indicated by light magenta bands in B, g = 0.45-0.5, cf. red and blue arrows in B) for a genome-wide sample of promoters (Table S1 ). Promoters with regulatory conflicts (e.g., cspA, magenta), are located in the gray quadrants. Promoters that respond to only one of the drugs (e.g., pheL, magenta) are located near the horizontal and vertical dotted lines. Promoters showing the same qualitative response to both drugs (e.g., sodA, magenta), are located in the white quadrants. Note that many promoters show conflicts for this drug pair. (D) As (C) but for TET-SPR drug combination. Most promoters lie in the white quadrants, showing that conflicts occur less frequently for this drug pair. However, some promoters show conflicts (e.g., slp and dnaX, magenta). Error bars in (B) correspond to two standard deviations estimated from replicate measurements done on different days (Experimental Procedures).
promoters that do not show regulatory conflicts, the response to the drug combination is unclear: Do promoters that show no response to the individual drugs (e.g., minC [ Figure 2B ]) respond to the combination? Do consistent responses, where a promoter is, e.g., upregulated in response to both drugs alone, typically lead to an amplified upregulation in the combination, as would be the case if a ''separation of variables'' scenario applied (Kaplan et al., 2008) ? To address these questions, we measured the regulatory response of our genome-wide sample of promoters to the simultaneous presence of two antibiotics. To resolve the effects of different drug concentration ratios, we set up 2D drug concentration matrices on 96-well plates and determined growth rates and gene expression levels in these conditions (103 3 96 = 9888 time curves) ( Figure 3A and Table 1 ). (C) Principal component analysis (PCA) is performed on the expression level matrices E x , yielding the principal components (PCs) E I , E II , . The scores s
. capture how strongly each PC contributes to the total response of promoter X (Experimental Procedures). Bar charts: Variance explained by the first five PCs for drug combination of TMP-SPR (left bar chart) and TET-SPR (right bar chart). Most variability is explained by the first PC, but the second PC is also important. Almost the entire data set is explained by the first three PCs, which thus capture the most typical features of the responses of all promoters.
Experimental Procedures). We performed these measurements for the antibiotic pair TMP-SPR, which triggers many gene regulatory conflicts ( Figure 2C ), as well as the antibiotic pair TET-SPR, which has fewer conflicts (cf. Figures 2C and 2D ). These two drug pairs show different drug interactions (Bliss, 1939; Loewe, 1928 Loewe, , 1953 : While TET and SPR show an additive interaction, i.e., their effect on growth when combined is essentially as if they were the same drug, the TMP-SPR combination shows an antagonistic interaction, i.e., at high concentrations of one drug, adding the other one has little effect on growth (Chait et al., 2007; Yeh et al., 2006) .
We observed a wide spectrum of gene expression responses to the TMP-SPR combination ( Figures 3B and S1 ). In general, the level of promoter expression in response to a combination of drugs lies between the expression levels it shows in the individual drugs, whether the drug actions on the promoter are in conflict (e.g., cspA in Figure 3B , hdeA and cysB in Figure S1A ), are consistent (e.g., sodA in Figure 3B , nhaA and pykF in Figure S1B ), or give no response (e.g., minC in Figure 3B , tolC and malZ in Figure S1C ). For promoters that respond to only one of the drugs when applied individually, the response to the drug combination is usually similar to the response to this drug alone (e.g., pheL in Figure 3D , serA and bioB in Figure S1D ). The TET-SPR drug combination shows broadly similar behavior ( Figure S2 ).
The Complete Response to Antibiotic Combinations Is Explained by Just a Few Principal Components
Our next goal was to identify general features of the response to these drug pairs. We used PCA to analyze the response of our genome-wide sample of promoters to the antibiotic pairs. PCA exposes the main modes of responses by removing redundancy and correlated data (Halabi et al., 2009; Jolliffe, 1986; Pearson, 1901) ; it represents the response of each promoter as a sum of a few basic ''principal component'' (PC) modes of response. If promoters respond in similar ways, the complete genome-wide sample of Figure 3 could potentially be represented by only few basic response modes.
We performed PCA on the gene expression response data sets for the TMP-SPR and TET-SPR drug combinations separately. In this analysis, we treated the expression levels E
x at different points in the 2D drug concentration space as variables ( Figures 3A and 3C ) and each different promoter X as an observation (Experimental Procedures). For both drug pairs, we find that almost all of the variability in the data (97%) is explained by just three PCs, with the first one capturing more than 70% of the variability, the second less than 25%, and the third about 2% ( Figure 3C ). Each gene expression response (E x ) to the drug combinations can therefore be presented as a linear superposition of only a few PCs:
x ,E III + / (where the same E I , E II , and E III are used for all promoters) ( Figure 3C ). This reduction in the number of variables means that the complete response of each promoter to the full 2D drug matrix can be specified by just three numbers, or ''scores''-s
x -a great simplification compared to the original representation, in which each promoter's response is described by the full set of expression levels at 96 positions in the 2D drug concentration space E Figure 3A) . Overall, this analysis revealed that the gene regulation response to antibiotic pairs has a relatively simple structure in that the responses of different promoters are largely captured by just two or three numbers.
What is the biological meaning of the first PC? Since the drugs affect growth rate, which in turn systematically affects gene expression (Brauer et al., 2008; Bremer and Dennis, 1996; Fazio et al., 2008; Gonzalez et al., 2002; Hua et al., 2004; Levy and Barkai, 2009; Scott et al., 2010) , we compared the different PCs with the measured growth inhibition in the 2D drug treatment. We found that for both drug pairs considered here, the first PC ( Figure 4A ) tracks the growth rate contour in the 2D drug concentration space ( Figure 4B ) remarkably precisely. Plotting the first PC along lines of constant growth rate shows that it is essentially constant along such growth rate isoboles ( Figure 4C ). This finding implies that the first PC can be approximately written as a function of only the growth rate: E I = F(g). This observation strongly suggests that the first PC captures the physiologically determined response to growth inhibition. Thus, for the two combinations we have studied, a large part of the gene regulation response to drug combinations is explained by growth inhibition rather than the specific effects of the drugs.
To remove growth-rate-dependent regulation from our analysis, we analyzed expression level changes along fixed growth rate isoboles in the two-drug space. To parameterize the position along an isobole in a combination of two drugs, A and B, we use a dimensionless measure-the ''effective drug fraction''-which measures the relative contributions of the drugs to growth inhibition (Experimental Procedures). This measure equals zero when only drug A is present, one when only drug B is present, and one-half when both drugs are present at concentrations leading to matched growth inhibition ( Figure 4C ). Using this growth-independent presentation, we next focused on the second PC as well as the response of individual promoters.
Cells Resolve Gene Regulatory Conflicts by Prioritizing or Averaging
For both drug pairs, the second PC varies from negative to positive values along a growth rate isobole ( Figures 5A and 5B) . Such a sign change in the expression level is the defining characteristic of a regulatory conflict. Consequently, this observation suggests that the second PC captures the general way in which cells resolve gene regulatory conflicts for a specific drug pair. Thus, it describes how promoters that are downregulated in one drug but upregulated in the other respond to the simultaneous presence of both drugs at different ratios. The second PC accordingly explains a larger fraction of the gene expression response for the TMP-SPR combination (20%, Figure 3C ), which shows many conflicts ( Figure 2C) , than for the TET-SPR combination (11%, Figure 3C ), which shows considerably fewer conflicts ( Figure 2D ).
In the TMP-SPR combination, the second PC shows a relatively sharp transition from a low to a high gene expression level when TMP is increasingly replaced with SPR at fixed growth rate ( Figure 5A ). This transition is not perfectly step-like, but occurs in a relatively narrow region in the 2D drug concentration space, dividing this space into two domains that show qualitatively different responses. These are the characteristic features of a prioritized response (cf. Figure 1B) . In particular, the response to the drug combination is similar to the response to the drug that has the stronger effect on growth at each given concentration ratio. In contrast, in the TET-SPR combination, the second PC along a growth rate isobole shows a much smoother transition, well approximated by a straight line as TET is continuously replaced with SPR ( Figure 5B )-the characteristic behavior of an averaged response (cf. Figure 1B) . The fact that the second component captures most of the variability in the data indicates that the solution of regulation conflicts for a given drug pair is very similar in all promoters. Indeed, almost all promoters in our genome-wide sample with clear gene regulatory conflicts show the same characteristic resolution of these conflicts: In TMP-SPR, 42 out of 44 promoters with clear regulatory conflict show prioritization, and in TET-SPR all promoters with conflicts show averaging (see Figures 5C, 5D , and S3). Resolution of regulation conflicts is not promoter specific; it is similar across different promoters genome-wide.
Response to Antibiotic Pairs Is Rarely Biased toward Either of the Two Drugs
We next looked for individual promoters whose prioritized responses are biased toward one of the drugs (cf. Figure 1B) . For the TET-SPR pair, there are no such biased responses, since gene regulatory conflicts are smoothly averaged for these drugs. For the TMP-SPR pair, however, we made use of the fact that the expression level along a growth rate isobole is well fit by a sigmoidal function for most promoters. The sigmoidal fit defines a transition point (x 0 ) for each promoter ( Figure 5E , inset, and Experimental Procedures). We found that the vast majority of promoters transition near x 0 = 1/2, where each of the drugs' individual contributions to growth inhibition are equal ( Figure 5E ). Thus, the relative impact of these drugs on growth inhibition coincides with their relative impact on the gene expression response; the cells primarily respond to the drug that inhibits their growth more severely.
We did find a small number of promoters that show a regulatory response that is biased toward one of the drugs. In particular, a few promoters are almost fully biased toward TMP (bars near x 0 = 1 in Figure 5E ), i.e., they show the response to TMP even if SPR is present at concentrations that have a stronger effect on growth. These promoters include hipB, which controls a toxin-antitoxin system, and the promoters serC, aroH, pheL, and serA ( Figure S4 ), which all play a role in amino acid biosynthesis (Keseler et al., 2009 ). The only promoter in our data set that is biased toward SPR is that of the antitoxin dinJ. In summary, these observations show that most promoters show an unbiased prioritized response (i.e., they respond to the drug with the greater effect on growth), with the notable exception of some genes in amino acid metabolism that respond almost exclusively to the TMP signal.
A Few Promoters Show Combination-Specific Responses to Antibiotic Combinations
The fact that most promoters show stereotypical behaviors captured by the first two PCs enabled us to identify promoters (C) Expression levels of genes dnaK, cspA, osmC, and dps in 2D drug concentration space of TMP-SPR. Gene expression levels along the growth rate isobole (dashed black line, normalized growth rate g = 0.5) are shown on the right. Magenta lines: sigmoidal fits (Experimental Procedures). Conflicts in gene expression are resolved in a prioritized response, leading to a relatively sharp transition between the conflicting expression levels as TMP is continuously replaced with SPR (cf. Figure 1B) . (D) As (B), but for different example genes ileX, dnaX, slp, and dps, which show conflicts in the 2D drug concentration space of TET-SPR. Magenta lines: linear fits (Experimental Procedures). Conflicts in gene expression are smoothly averaged, leading to a linear transition between the conflicting expression levels (cf. Figure 1B) . (E) Inset: Schematic of sigmoidal fits to curves from (A) and (C) with fit parameter x 0 characterizing the position of the transition between the two different gene expression responses. Histogram of fit results for x 0 for drug combination of TMP-SPR is shown(Experimental Procedures). The distribution of x 0 is narrowly localized around 0.5, showing that the response of most genes is not biased toward either of the drugs (cf. Figure 1C) , though a few genes are biased toward TMP (bars near x 0 = 1). Error bars correspond to two standard deviations estimated from replicate measurements done on different days (Experimental Procedures). that show responses to the two-drug environment that deviate from this norm. To this end, we calculated the scores s
. of the different PCs for each promoter ( Figure 3C ). These scores reflect how strongly each PC contributes to the promoter's response. Promoters with responses that are not captured by the first two PCs have large scores for the higher PCs, such as the third PC ( Figure 6A ). The third PC exhibits a clear peak in the TMP-SPR drug combination, i.e., unlike the first two PCs, it describes expression levels in the drug combination that do not fall between the expression levels in the individual drugs ( Figure 6B ). This observation suggests that the third PC captures the drug combination-specific response of promoters whose expression levels in the drug combination lie outside the range bounded by the expression levels in the individual drugs. Indeed, promoters with a large score for the third PC show such drug combination-specific responses ( Figures  6C, 6D, and S5A ).
An example is the lexA promoter, which controls transcription of the master regulator of the DNA damage (''SOS'') response (Walker, 1996) . This promoter is upregulated in response to TMP (Mesak et al., 2008; Walker, 1996) and slightly upregulated in response to SPR, but shows no upregulation or even a slight downregulation in the drug combination ( Figure 6C ). This observation could be explained by the idea that adding translation inhibitors like SPR to TMP leads to a reduction in the amount of DNA damage in the cell. Another interesting case is slp, a promoter known to respond to starvation conditions (Keseler Figure 6D ). The fact that this promoter is regulated by multiple transcription factors (GadW, GadX, and possibly MarA) suggests that such drug combination-specific responses usually require the integration of more than one regulatory input. Consistent with this view, the glyA promoter, which shows a combination-specific response ( Figures 6A and S5A ), is regulated by two different transcription factors (PurR and MetR) (Keseler et al., 2009 ). This view is further supported by the fact that the only promoter that shows a combination-specific response to the TET-SPR combination (uspA) ( Figure S5B ) is also regulated by two different transcription factors. In summary, we found that only a few promoters do not strictly follow the general rule set by the first and second PCs, but instead show drug combinationspecific responses. These promoters often have multiple transcriptional regulatory inputs. Identifying such genes and their regulation may be important to advance our understanding of cellular responses to drug combinations.
Increased Cell-to-Cell Variability in Gene Expression Occurs at the Transition Point of a Prioritized Response
We have shown that cells can average the responses to individual drugs in a drug combination (Figures 5B and 5D ). However, this averaged response was observed at the population level and could in principle be due to a stochastic response at the single-cell level (Eldar and Elowitz, 2010; Gefen and Balaban, 2009; Gefen et al., 2008; Rotem et al., 2010) in which different subpopulations of cells randomly show the response to either one of the two drugs (cf. Figure 1C ). To fully discriminate between different possible response strategies to drug combinations (Figure 1) , we need to investigate cell-to-cell variability in gene expression responses. To this end, we measured transcriptional responses to drug combinations in single cells. Specifically, we integrated ten GFP transcriptional reporters (Zaslaver et al., 2006) into the E. coli chromosome to avoid noise caused by plasmid copy number variability (Elowitz et al., 2002; Freed et al., 2008 ) (Experimental Procedures). We selected promoters that show clear regulatory conflicts in either the TMP-SPR or the TET-SPR drug combination ( Figures 5C and 5D ), but also a few promoters that show no clear conflicts or unusual behaviors ( Figure 6 and Table S1 ). We then grew these strains in 2D concentration gradients of either TMP-SPR or TET-SPR (Figure 3A) , imaged cells at a fixed time point, and quantified single-cell GFP fluorescence using automated image analysis ( Figure 7A and Experimental Procedures). For each promoter, we sampled at least eight different drug conditions that reflect different drug ratios at fixed growth inhibition.
We found unimodal distributions of expression levels in all conditions. This observation indicates that bimodal stochastic responses to drug combinations ( Figure 1C) are rare, even when the drugs elicit conflicting responses. Hence, our analysis of population level measurements (Figures 2-6 ) does not suffer from this potential complication. Importantly, for promoters that show a prioritized response to the TMP-SPR combination, we found that expression level cell-to-cell variability, measured by the variation coefficient, often has a clear peak in the drug (B) Population average measurements of expression level E x (black circles) along growth rate isobole g = 0.5 as in Figure 5C , for promoters cspA, ileX, and glyA in TMP-SPR drug combination. Black lines are sigmoidal fits (cf. Figure 5 ) except for glyA where black line shows cubic spline. Blue circles show variation coefficient of GFP/cell along a similar growth rate isobole. The coefficient of variation (CV) is a measure of the relative cell-to-cell variability in gene expression and defined as the empirical standard deviation of GFP/cell (shown in A) divided by its mean (Experimental Procedures). Blue lines are cubic splines. Gene expression cell-to-cell variability peaks in drug combination near the point where a sharp transition between two different responses occurs. (C) As (B) but for TET-SPR showing promoters rpmE, ileX, and glyA, which have regulatory conflicts in this drug combination. Note that gene expression cell-tocell variability does not peak in the drug combination. combination ( Figure 7B ). This peak is located near the point where a sharp transition in gene expression level occurs (Figure 7B ). Near such a sharp transition, small fluctuations in the detection of the drugs by bacteria (''input noise'' [Tkacik et al., 2008] ) may be amplified to yield large fluctuations in gene expression level (''output noise''). This role of input noise offers a plausible explanation for the observed increase in cell-to-cell gene expression variability at the boundary between the two sharply separated response domains in the 2D drug space. Consistent with this view, cell-to-cell variability did not exhibit peaks for any promoter showing a conflict in the TET-SPR combination, where conflicts do not lead to sharp transitions between the different expression level states but are smoothly averaged ( Figure 7C ). These observations provide further support for our conclusion that gene regulatory conflicts lead to two sharply separated response domains in the TMP-SPR drug combination while they are smoothly averaged in the TET-SPR combination.
DISCUSSION
We found that regulatory conflicts in which a gene is upregulated in response to drug A and downregulated in response to drug B (Figure 1 ) play a key role in the bacterial gene regulation response to combinations of antibiotics. Such conflicts occur for many genes, in particular when the two drugs have different modes of action (Figure 2 ). Using PCA, we found that over 70% of the gene regulation response to antibiotic combinations can be explained simply as a response to the growth rate change caused by the drugs (Figures 3 and 4) . Importantly, the remainder of the response is almost entirely captured by generic ways of gene regulatory conflict resolution in a given drug combination: (1) Cells can linearly superpose (''average'') the responses to the individual drugs, or (2) they can ''prioritize'' their response to one of the drugs and essentially ignore the presence of the other drug ( Figure 5 , cf. Figure 1) . Which mode of conflict resolution is used depends on the drug pair, but applies to virtually all genes that show conflicting regulation. Only a few genes show responses to drug combinations that are not explained by growth rate effects and conflict resolution alone (Figure 6 ). Finally, for the prioritized response, we found that the cell-tocell variability in gene expression peaks when both drugs are present, at the location in two-drug space where the cells switch their response from one drug to the other (Figure 7) . Together, these results show that there are relatively simple, general relations between the transcriptional responses to drug combinations and those to the individual drugs.
It is striking that just two PCs largely explain the bacterial response to antibiotic combinations. While these PCs generally have nontrivial shapes that depend on the drug pair, only two numbers (scores) suffice to characterize the complete response of a given promoter once the PCs are known ( Figure 3C ). The first score, s 1 x , quantifies how strongly promoter X responds to growth rate changes. The second score, s 2 x , measures the extent to which the promoter shows the drug pair stereotypical conflict resolution. The fact that these two numbers are enough to capture the response of most promoters implies that the full response matrix to the two-drug environment can be predicted from a relatively small number of measurements: Once the first two PCs for a given drug pair are identified (which can be done by measuring the gene expression response to the full twodrug environment for a relatively small number of genes), three measurements (e.g., no drug, single dose of drug A, and single dose of drug B) would suffice to determine the first two scores, s 1 x and s 2 x , for that gene. From these scores, a prediction for the expression levels across the entire two-drug space can be readily calculated. Hence, our results provide a way to predict the transcriptional response to a drug combination for most genes from their response to the individual drugs.
A notable observation we made is that the response of the vast majority of genes is not biased toward either of the drugs (cf. Figure 1B) : The transition between the two sharply separated response domains of a prioritized response occurs almost exactly at the point where growth inhibition by both drugs (TMP and SPR) is equally strong ( Figure 5E ). Interestingly, these two drugs have an antagonistic/buffering effect on growth (Bollenbach et al., 2009; Chait et al., 2007) , i.e., adding one drug at low concentration when the other one is present at higher concentration does not lead to a decrease in growth. These observations are consistent with a simple scenario in which the cells' response is primarily determined by (1) the overall growth inhibition (first PC) and (2) the drug that limits their growth (second PC). If present, the third PC may describe promoters that show specific responses to both drugs, including the drug that does not limit growth. While this picture appears plausible, more work will be needed to elucidate the mechanism that underlies the observed strategies of conflict resolution. Specifically, one could measure the levels of factors that act upstream of promoters (such as guanosine tetraphosphate, ppGpp) in two-drug environments. In addition, one could study the effects on conflict resolution of targeted genetic manipulations that affect such global regulators (e.g., relAspoT deletions).
Moreover, it will be interesting to investigate the questions addressed in this article for a large set of different drugs with a range of different cellular targets (including DNA replication, cell wall synthesis, and translation) (Walsh, 2003) and different pairwise drug interactions (additive, synergistic, and antagonistic) (Bliss, 1939; Loewe, 1928 Loewe, , 1953 Yeh et al., 2006) . Furthermore, it will be promising to extend our investigation to much higher concentrations of both bacteriostatic and bactericidal drugs. This approach would help to identify which types of drug pairs lead to conflict resolution by averaging, which ones lead to prioritization and if there are drug pairs that trigger yet other behaviors. Such a comprehensive data set might allow us to reveal a general relation between the drug interaction or mechanism similarity and the cellular strategy for the resolution of regulatory conflicts in the combination.
The approach presented here, in particular the PCA of gene expression responses to drug combinations, is generally applicable to other organisms, including yeast and human cancer cell lines, different types of drugs, and to combinations of more than two drugs. Extending our approach to yeast would be relatively straightforward, since similar tools for fluorescencebased transcriptional measurements (Huh et al., 2003) and drugs with similar modes of action are available. In other model systems, GFP-reporter libraries covering a considerable part of the genome may have to be constructed first (Cohen et al., 2008) . Alternatively, other methods for genome-wide measurements of mRNA or protein levels could be adapted to extend the approach described here to other systems. Independently of methodology, it will be interesting to see to what extent the behaviors identified in this study extend to other systems. It is quite possible that eukaryotes, in which transcriptional regulation is more complex than in prokaryotes, may resolve gene regulatory conflicts in new, unexpected ways. The long-term prospect of predicting the cellular response to a multidrug treatment from the responses to the individual drugs may lay the foundation for controlling cellular gene expression by targeted combinations of drugs (Geva-Zatorsky et al., 2010) . In particular, multidrug combinations may be designed in ways that exploit gene regulatory conflicts to restore a healthy cell state in human tissues, to circumvent cellular defense strategies, or to slow down the evolution of drug resistance in chemotherapy.
EXPERIMENTAL PROCEDURES
Media, Strains, and Drugs Experiments were conducted in M9 minimal medium with 0.4% glucose as carbon source and 0.2% amicase. Drug solutions were made from powder stocks, filter-sterilized, stored at À20 C in the dark, and added as indicated.
All strains used were derived from E. coli K-12 strain MG1655. Promoter-GFP constructs for cspA, rmf, rpmE, dps, glyA, slp, recA, rrsA, wrbA, and ileX (Zaslaver et al., 2006) were integrated into the attTn7 locus of strain MG1655 as described (McKenzie and Craig, 2006) . We used primers GGGGACCACTTTGTACAAGAAAGCTGGGTCCGATTCTGATAACAAACTAG CAACACC and GGTGAAGACGAAAGGGCCTCGTAGAGCCTGCTTTTTTGTA CAAACTTGTCCCC for PCR and BP Clonase (Invitrogen) to move promoter-GFP constructs into the delivery plasmid pGRG37. This plasmid was slightly modified such that the cloning reactions could be performed with BP Clonase and attB-flanked PCR products. Wild-type MG1655 were transformed with this plasmid. Integrations at the attTn7 site were verified by colony PCR using primers GATGACGGTTTGTCACATGGA and CCCCTATAGTGAGTCGTATTA CATGG. Curing of the delivery plasmid in final strains was verified by testing for ampicillin sensitivity.
Growth Rate and Gene Expression Assay
Overnight cultures were diluted $200-fold and grown on an automated robotic system (Caliper) at 30 C with rapid shaking in 96-well microtiter plates (Costar) containing 200 ml medium per well. Absorbance at 600 nm (A 600 , proportional to optical density OD 600 via OD 600 = 3.1 A 600 ) and GFP fluorescence were recorded by a plate reader (Victor III, Perkin-Elmer) at intervals of 35-55 min for 24 hr and then background subtracted. Growth rates were calculated using Matlab (The MathWorks) by linear regression of log(OD 600 ) (Matlab function ''regress'') during exponential growth (0.02 < A 600 < 0.3). The measurement error was evaluated as the 95% confidence interval of the linear regression and was typically well below 10%. The growth rate at each drug concentration was obtained as the median growth rate over the whole set of GFP reporter strains measured in identical drug conditions. MIC was defined as the lowest concentration at which background-subtracted A 600 did not exceed 0.02 after 24 hr. GFP background of GFP reporter strains was subtracted as previously described (Zaslaver et al., 2006 ). We defined the expression level as the mean GFP/A 600 in the interval 0.04 < A 600 < 0.3 (Figure 2A ). Only promoters with a clearly detectable GFP signal were used for analysis, reducing the total number to 93 promoters ( Figures 2C and 2D) . Expression level changes (g) relative to the drug-free control were normalized to the median expression level change (g) of all promoters in the same drug environment. Changes in the median expression level of all promoters reflect nonspecific effects such as pH changes or changes of the reporter plasmid copy number. We previously verified that the effect of plasmid copy number on the measured expression level is independent of the GFP promoter (Bollenbach et al., 2009 ). Error bars in Figures 2, 5 , S3, and S4 were calculated from day-to-day variability of replicate measurements as previously described (Bollenbach et al., 2009 ). The white regions in the top right of panels that show promoter expression in 2D drug environments (Figures 4, 5, 6 , S1, S2, S3, and S5) reflect no data due to low growth rates or drug concentrations not sampled.
2D drug concentration matrices were set up on 96-well plates (see black dots in Figure 4A for concentrations used). Expression levels along growth rate isoboles were calculated by linear interpolation using Matlab functions ''griddata'' (for the TET-SPR data set) and ''interp2'' (for the TMP-SPR data set). The ''effective drug fraction'' ( Figures 4C, 5, 7B , and 7C) is defined as I SPR =ðI TMP + I SPR Þ, where I D is the relative growth inhibition at the same concentration of drug D alone: I D = 1 À g with the normalized growth rate g.
Linear fits shown in Figures 5B, 5D , 7C, and S3B were performed by fitting the function fðxÞ = mx + b to the data with m and b as fit parameters using Matlab function ''fit.'' Sigmoidal fits were performed by fitting the function gðxÞ = h tanhððx À x 0 Þ=wÞ + r to the data, using x 0 , w, h, and r as fit parameters in Matlab function ''fit.'' Here, x 0 is the position of the transition ( Figure 5E , inset), w is a measure for the width of this transition, h measures the magnitude of gene regulatory conflict, and r reflects the expression level change due to growth rate.
Only promoters with R 2 > 0.8 were used in the analysis of sigmoidal fits (Figure 5E) . Lower values of R 2 typically occurred for promoters with no regulatory conflict, such that a sigmoidal fit to a constant expression level along the growth rate isobole did not yield meaningful results for the fit parameters x 0 and w.
Single-Cell Fluorescence Microscopy Assay
Cultures of chromosomally integrated promoter-GFP reporter strains were grown to A 600 $0.14, mounted on agar pads, and imaged (GFP fluorescence and phase contrast). For each reporter strain, the exposure time was adjusted to ensure that the highest signal was well below detector saturation. Several hundred cells of each reporter strain were imaged in 8-11 different drug conditions, and background fluorescence was subtracted. Images were segmented automatically using custom Matlab code ( Figure 7A ) and manually verified. GFP fluorescence per cell ( Figure 7 ) was defined as the maximum GFP intensity detected in the area of each cell (using the mean or median GFP intensity yielded similar results).
Principal Component Analysis
PCA was performed on the expression level matrices E x , treating the expression levels at all positions in the 2D drug concentration space as variables and the corresponding expression levels of the different promoters at these positions as observations ( Figure 3C ). PCA was performed independently on the TMP-SPR and TET-SPR data sets using Matlab function ''princomp.'' Only promoters with a clearly detectable GFP signal were used for PCA (Table  S1 ). Only drug concentrations at which data was available for all promoters were used in PCA (at high concentrations of both drugs, some reporter strains did not reach sufficiently high OD values).
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